Liquid biopsy epigenomic profiling for cancer subtypingSylvan C. Baca, Matthew L. Freedman, Ji-Heui Seo et al.|Nature Medicine|2023Cited by 119
Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitorsAmin H. Nassar, Alexander Gusev, Kent W. Mouw et al.|Cancer Cell|2022Cited by 117
Germline variants associated with toxicity to immune checkpoint blockadeStefan Groha, Alexander Gusev, Sarah Abou Alaiwi et al.|Nature Medicine|2022Cited by 106
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) ConsortiumTalal El Zarif, Danai Dima, Amin H. Nassar et al.|Journal of Clinical Oncology|2023Cited by 69
Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes studyZiad Bakouny, Deborah B. Doroshow, C. Labaki et al.|Annals of Oncology|2022Cited by 33